Broadly neutralizing non-antibody protein for treating clostridium difficile infection

用于治疗艰难梭菌感染的广泛中和非抗体蛋白

基本信息

  • 批准号:
    9293991
  • 负责人:
  • 金额:
    $ 22.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-06-10 至 2019-05-31
  • 项目状态:
    已结题

项目摘要

Abstract Clostridium difficile infection (CDI) is the leading cause of infectious diarrhea in hospitalized patients, with an estimated annual cost to the United States of between $750 million and $3.2 billion. The pathology of CDI is caused by the toxins secreted by the bacteria. Recently, two anti-C. difficile toxin antibodies, actoxumab and bezloxumab, that bind to and neutralize C. difficile toxins A and B, respectively, have achieved success for CDI treatment in a phase II clinical trial. However, only bezloxumab demonstrated efficacy in the subsequent phase III clinical trial. The neutralization potency of antibody is strongly epitope-dependent. Since both actoxumab and bezlotoxumab were engineered using toxins from laboratory C. difficile strain VPI 10463, both showed significantly reduced neutralization potencies against some recently emerged hypervirulent strains of C. difficile. Thus, there is an urgent need to develop broadly effective C. difficile toxins neutralizer. We propose to engineer a non-antibody protein, designed ankyrin repeat protein (DARPin), that is able to bind to and neutralize toxins A and B from a broad range of C. difficile strains. DARPins represent a versatile class of binding proteins that have been engineered to bind diverse targets with up to picomolar affinity. Furthermore, DARPin can be very efficiently expressed in E. coli (accounting for >50% of all E. coli proteins) and very easily purified due to its high thermostability. In this project, we will first use bacteriophage display to isolate DARPins that are able to bind to toxins from different strains of the C. difficile (Aim 1) and then subject the selected DARPins to an anti-toxin functional screen in cultured cells to identify toxin-neutralizing DARPins (Aim 2). The potency of the selected DARPins against a panel of emerging and clinically relevant strains of C. difficile will be analyzed and be further optimized by directed evolution (Aim 3). Successful completion of this study will yield an arsenal of high-potency toxin-neutralizing DARPins. These broadly neutralizing anti-toxin DARPins can potentially be fused to Fc and used as antibody therapy for CDI, or be formulated for oral administration to directly neutralize C. difficile toxin(s) in the gut. The approach of neutralizing bacterial virulence factors with DARPins should also offer a new treatment paradigm for other bacterial infection.
摘要 艰难梭菌感染(CDI)是住院患者感染性腹泻的主要原因, 估计美国每年的成本在7.5亿美元到32亿美元之间。CDI的病理是 是由细菌分泌的毒素引起的最近,两个抗C。艰难梭菌毒素抗体、阿克妥尤单抗和 贝佐单抗,其结合并中和C.艰难梭菌毒素A和B分别在CDI中取得了成功 在II期临床试验中进行治疗。然而,只有贝珠单抗在后续阶段显示出疗效 III临床试验。抗体的中和效力具有强烈的表位依赖性。由于阿克妥尤单抗 和贝兹洛木单抗使用来自实验室C的毒素进行工程改造。艰难梭菌菌株VPI 10463,均显示 显著降低了对最近出现的一些C. 很难因此,迫切需要开发广泛有效的C。艰难毒素中和剂。我们建议 工程化非抗体蛋白,设计的锚蛋白重复蛋白(DARPin),其能够结合并 中和来自广泛范围的毒素A和B。艰难菌株DARPins代表了一种多功能的 结合蛋白已经被改造成以高达皮摩尔的亲和力结合不同的靶标。此外,委员会认为, DARPin可在E.大肠杆菌(占大肠杆菌总数的50%以上)。大肠杆菌蛋白质), 由于其高的热稳定性而纯化。在这个项目中,我们将首先使用噬菌体展示来分离DARPins 能够与不同的C.艰难(目标1),然后将选定的 DARPins用于在培养的细胞中进行抗毒素功能筛选以鉴定毒素中和DARPins(Aim 2)。的 所选DARPin对一组新出现的和临床相关的C.困难将是 分析并通过定向进化(Aim 3)进一步优化。成功完成这项研究将产生 一系列高效毒素中和DARPins。这些广泛中和的抗毒素DARPin可以 可能与Fc融合并用作CDI的抗体治疗,或配制用于口服给药, 直接中和C.肠内艰难梭菌毒素。细菌毒力因子的中和途径 DARPins还应该为其他细菌感染提供新的治疗模式。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Structural dynamics of receptor recognition and pH-induced dissociation of full-length Clostridioides difficile Toxin B.
  • DOI:
    10.1371/journal.pbio.3001589
  • 发表时间:
    2022-03
  • 期刊:
  • 影响因子:
    9.8
  • 作者:
    Jiang M;Shin J;Simeon R;Chang JY;Meng R;Wang Y;Shinde O;Li P;Chen Z;Zhang J
  • 通讯作者:
    Zhang J
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zhilei Chen其他文献

Zhilei Chen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zhilei Chen', 18)}}的其他基金

Oral Protein Therapeutics Against C. difficile Associated Colitis
针对艰难梭菌相关结肠炎的口服蛋白质疗法
  • 批准号:
    10455793
  • 财政年份:
    2021
  • 资助金额:
    $ 22.51万
  • 项目类别:
A Novel Technology for Engineering Binders to Membrane Proteins
膜蛋白结合剂工程新技术
  • 批准号:
    10040547
  • 财政年份:
    2020
  • 资助金额:
    $ 22.51万
  • 项目类别:
A Novel Technology for Engineering Binders to Membrane Proteins
膜蛋白结合剂工程新技术
  • 批准号:
    10227122
  • 财政年份:
    2020
  • 资助金额:
    $ 22.51万
  • 项目类别:
Internal Toxin Neutralizer for Treating STEC-infection
用于治疗 STEC 感染的内毒素中和剂
  • 批准号:
    9886184
  • 财政年份:
    2019
  • 资助金额:
    $ 22.51万
  • 项目类别:
Artificial Ecology Sink as prophylaxis against viral infection
人工生态水槽预防病毒感染
  • 批准号:
    9348755
  • 财政年份:
    2017
  • 资助金额:
    $ 22.51万
  • 项目类别:
Broadly neutralizing non-antibody protein for treating clostridium difficile infection
用于治疗艰难梭菌感染的广泛中和非抗体蛋白
  • 批准号:
    9167525
  • 财政年份:
    2016
  • 资助金额:
    $ 22.51万
  • 项目类别:
Isolation of Genetic Suppressor Elements Against Hepatitis C Virus
抗丙型肝炎病毒基因抑制元件的分离
  • 批准号:
    7905080
  • 财政年份:
    2009
  • 资助金额:
    $ 22.51万
  • 项目类别:
Isolation of Genetic Suppressor Elements Against Hepatitis C Virus
抗丙型肝炎病毒基因抑制元件的分离
  • 批准号:
    7708619
  • 财政年份:
    2009
  • 资助金额:
    $ 22.51万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 22.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 22.51万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 22.51万
  • 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 22.51万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 22.51万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 22.51万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 22.51万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 22.51万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 22.51万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 22.51万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了